t3912

Ozenoxacin (T-3912) is a quinolone antibacterial. It shows potent activities against the main microorganisms isolated from soft tissue and skin infections.

Saponin activator. Activates release of Prostaglandin E2 in vitro. Anti-inflammatory agent. Orally active. Active in vivo and in vitro.

Fluoroethylnormemantine, a derivative of Memantine, acts as an N-methyl-D-aspartate (NMDA) receptor antagonist and can function as a positron emission tomography (PET) tracer known as [18F]-fluoroethylnormemantine. This compound displays anti-amnesic, neuroprotective, antidepressant-like, and fear-attenuating properties.

Odatroltide is a nanoscale P-selectin inhibitor that serves as a nano-delivery system for 6,7-dihydroxyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid and KPAK to specifically target the thrombus.

Inclisiran sodium (ALN-PCSsc sodium) is a dual-strand siRNA conjugated with triantennary N-acetylgalactosamine (GalNAc), with antihypertensive activity. It inhibits the transcription of PCSK9, reducing the hepatic synthesis of proprotein convertase subtilisin/kexin type 9, and can be used in cardiovascular disease research.

Givosiran (ALN-AS1) is a small interfering RNA compound that selectively targets hepatic aminolevulinate synthase 1 (ALAS1) mRNA, leading to efficient downregulation of ALAS1 expression and consequent inhibition of neurotoxic δ-aminolevulinic acid and porphobilinogen accumulation. Givosiran provides a mechanism-driven research tool with significant relevance for studying metabolic dysregulation and therapeutic intervention strategies in acute intermittent porphyria.

BAY 1217224 is a neutral, non-prodrug thrombin inhibitor with favorable oral pharmacokinetics.

MC-vc-PAB-Tubulysin M is a conjugate comprising a cleavable ADC linker (MC-vc-PAB) and the cytotoxic tubulin inhibitor Tubulysin M, which inhibits tubulin polymerization, leading to cell cycle arrest and apoptosis.

Zunsemetinib (ATI-450) is an orally active and selective inhibitor of the p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway.Zunsemetinib is used to study spondyloarthritis and rheumatoid arthritis.

Pro-Phe-Phe, a highly aggregation-prone tripeptide composed of natural amino acids, exhibits the formation of distinctive helical-like sheets that engage in aromatic dry interfaces. This property makes Pro-Phe-Phe an excellent candidate for the development of modular super-helical self-assembling nanostructures.

BMS-986143, an orally active, reversible BTK inhibitor with an IC50 value of 0.26 nM, is designed for autoimmune disease research. Additionally, it targets TEC, BLK, BMX, TXK, FGR, YES1, and ITK, exhibiting IC50s of 3 nM, 5 nM, 7 nM, 10 nM, 15 nM, 19 nM, and 21 nM, respectively [1].